“We continue to build significant momentum across our cardiac pipeline, and the recent financing strengthens our ability to execute on essential manufacturing and commercial activities for LX2006 as we look towards registrational readiness,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics (LXEO). “Interim clinical data for LX2006 demonstrate meaningful benefit across measures of cardiac health and neurologic function, including improvements in the modified Friedreich Ataxia Rating Scale, and we believe this therapy could represent a transformational step forward in the standard of care for FA. Furthermore, with enrollment complete in the HEROIC-PKP2 Phase I/II trial, we look forward to sharing new clinical data for LX2020 in January.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright
- Lexeo Therapeutics Advances Study on Friedreich Ataxia-Associated Cardiomyopathy
- Lexeo Therapeutics Advances Gene Therapy Study for Genetic Heart Condition
- Lexeo Therapeutics Advances Research in Genetic Cardiomyopathy with New Study Update
- Lexeo Therapeutics Advances Gene Therapy Study for Rare Heart Condition